These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 21532492

  • 1. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, Han SW, Oh DY, Lee HJ, Kim TY, Kim WH, Yang HK, Bang YJ.
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [Abstract] [Full Text] [Related]

  • 2. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [Abstract] [Full Text] [Related]

  • 3. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W, Zhong S, Chen J, Yu Y.
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [Abstract] [Full Text] [Related]

  • 4. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A.
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [Abstract] [Full Text] [Related]

  • 5. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G, Aranda FI, Adrover E, Niveiro M, Alenda C, Payá A, Seguí J.
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [Abstract] [Full Text] [Related]

  • 6. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q.
    World J Gastroenterol; 2013 Jan; 19(14):2171-8. PubMed ID: 23599643
    [Abstract] [Full Text] [Related]

  • 7. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R, Fassan M, Hanspeter E, Bornschein J, d'Amore ES, Cuorvo LV, Mazzoleni G, Barbareschi M, Pizzi M, Guzzardo V, Malfertheiner P, Micev M, Guido M, Giacomelli L, Tsukanov VV, Zagonel V, Nitti D, Rugge M.
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [Abstract] [Full Text] [Related]

  • 8. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 9. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
    Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M, ACTS-GC Group.
    Clin Cancer Res; 2012 Nov 01; 18(21):5992-6000. PubMed ID: 22977193
    [Abstract] [Full Text] [Related]

  • 10. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN.
    Eur Urol; 2011 Aug 01; 60(2):350-7. PubMed ID: 21640482
    [Abstract] [Full Text] [Related]

  • 11. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S.
    Gynecol Oncol; 2005 Jul 01; 98(1):24-30. PubMed ID: 15894362
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK.
    Hum Pathol; 2012 Mar 01; 43(3):413-22. PubMed ID: 21855114
    [Abstract] [Full Text] [Related]

  • 13. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
    Sornmayura P, Rerkamnuaychoke B, Jinawath A, Euanorasetr C.
    J Med Assoc Thai; 2012 Jan 01; 95(1):88-95. PubMed ID: 22379747
    [Abstract] [Full Text] [Related]

  • 14. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J, Jeong J, Sung J, Sung CO, Kim KM, Park CK, Choi MG, Sohn TS, Bae JM, Kim S.
    Ann Surg Oncol; 2013 Dec 01; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [Abstract] [Full Text] [Related]

  • 15. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
    Han X, Shi Y, Ma L, Lyu Z, Yang H, Yao J, Li J, Li B, Qin Y.
    Chin Med J (Engl); 2014 Dec 01; 127(2):246-53. PubMed ID: 24438611
    [Abstract] [Full Text] [Related]

  • 16. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A.
    Am J Surg Pathol; 2012 Apr 01; 36(4):577-82. PubMed ID: 22314190
    [Abstract] [Full Text] [Related]

  • 17. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.
    J Clin Oncol; 2005 Jul 01; 23(19):4287-97. PubMed ID: 15994142
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW, Chuang TC, Yang AH, Hsu CK, Kao MC.
    Int J Oncol; 2005 Apr 01; 26(4):933-43. PubMed ID: 15753987
    [Abstract] [Full Text] [Related]

  • 19. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 20. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, Salto-Tellez M.
    J Clin Pathol; 2011 Oct 01; 64(10):880-3. PubMed ID: 21757431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.